BACKGROUND:: Rosuvastatin is a new statin indicated to reduce elevated levels of total
cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase …

Background: Rosuvastatin is a fully synthetic statin developed by AstraZeneca. It is a
competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase. Objective: We reviewed …

Rosuvastatin, a new hydrophilic 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase
inhibitor (statin), is approved as an adjunct to diet in patients with primary …

OBJECTIVE: To review the currently available information on rosuvastatin in the treatment of
primary hypercholesterolemia. DATA SOURCES: MEDLEY (2000–January 2001), MEDLIT …

Rosuvastatin is a synthetic statin that represents an advance in the pharmacologic and
clinical properties of statins. Relative to other statins, rosuvastatin possesses a greater …

Purpose. The chemistry, pharmacology, pharmacokinetics, drug interactions, clinical
efficacy, adverse effects, dosage and administration, and place in therapy of rosuvastatin are …

Abstract▴ Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin is not extensively …

The HMG-CoA reductase inhibitor (statin) rosuvastatin (Crestor®) is widely available for use
in the management of dyslipidemia, and was recently approved in the US to slow the …

Background: The HMG Co-A reductase inhibitors (statins) are the most efficacious agents for
lowering cholesterol. Statins reduce clinical cardiovascular events and are generally well …

BACKGROUND: This double-blind, multicenter, randomized trial compared rosuvastatin and
atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with …